IS6338A - 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor - Google Patents

4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor

Info

Publication number
IS6338A
IS6338A IS6338A IS6338A IS6338A IS 6338 A IS6338 A IS 6338A IS 6338 A IS6338 A IS 6338A IS 6338 A IS6338 A IS 6338A IS 6338 A IS6338 A IS 6338A
Authority
IS
Iceland
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
cetp inhibitor
Prior art date
Application number
IS6338A
Other languages
Icelandic (is)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Robinson Brostrom Lyle
Lawrence Tickner Derek
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6338A publication Critical patent/IS6338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
IS6338A 1999-11-30 2002-04-12 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor IS6338A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
IS6338A true IS6338A (en) 2002-04-12

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6338A IS6338A (en) 1999-11-30 2002-04-12 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558D0 (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
TNSN03139A1 (en) 2001-06-21 2005-12-23 Pfizer Prod Inc SELF-EMULSIBLE FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
GT200200170A (en) 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
KR100664822B1 (en) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 Process for preparing homogeneous spray-dried solid amorphous drug dispersions using a modified spray-drying apparatus
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ES2277142T3 (en) 2002-08-30 2007-07-01 Japan Tobacco Inc. DIBENCILAMINE COMPOSITE AND ITS MEDICINAL USE.
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CN1795177A (en) * 2003-03-28 2006-06-28 辉瑞产品公司 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
MXPA06001417A (en) 2003-08-04 2006-05-15 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials.
PL1670768T3 (en) 2003-10-08 2010-01-29 Lilly Co Eli Compounds and methods for treating dyslipidemia
US7737295B2 (en) * 2004-04-13 2010-06-15 Merck Sharp & Dohme Corp. CETP inhibitors
JP2008504266A (en) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー Compounds and methods for treating dyslipidemia
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
BRPI0608553A2 (en) 2005-02-24 2010-01-12 Millennium Pharm Inc pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
TWI450896B (en) 2009-06-30 2014-09-01 Lilly Co Eli Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
RU2703192C2 (en) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Genetic markers for predicting response to therapy by raising hdl level or imitating hdl agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
JP2003515592A (en) 2003-05-07
GT200000199A (en) 2002-05-23
CO5271716A1 (en) 2003-04-30
IL149097A0 (en) 2002-11-10
MA26845A1 (en) 2004-12-20
HUP0203521A2 (en) 2003-02-28
PA8506301A1 (en) 2002-08-26
TNSN00231A1 (en) 2002-05-30
KR20020058057A (en) 2002-07-12
PL355892A1 (en) 2004-05-31
OA12099A (en) 2006-05-04
WO2001040190A1 (en) 2001-06-07
NO20022558L (en) 2002-05-29
TR200201446T2 (en) 2002-11-21
EP1246804A1 (en) 2002-10-09
EE200200277A (en) 2003-10-15
NO20022558D0 (en) 2002-05-29
AP2002002531A0 (en) 2002-06-30
UY26454A1 (en) 2001-07-31
MXPA02005354A (en) 2002-12-11
BG106854A (en) 2002-12-29
EA200200510A1 (en) 2002-10-31
AU1048801A (en) 2001-06-12
CA2392979A1 (en) 2001-06-07
PE20010904A1 (en) 2001-09-10
BR0015836A (en) 2002-08-06
CN1402711A (en) 2003-03-12
ECSP003792A (en) 2002-04-23

Similar Documents

Publication Publication Date Title
NO20022558D0 (en) 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor
DK1114033T3 (en) 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors
NO20011350L (en) 4-Carboxyamino Substituted 1,2,3,4-Tetrahydroquinolines as CETP Inhibitors
IS2278B (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline inhibited by CETP
ATE240327T1 (en) 1,2-ANNELATED QUINOLINE DERIVATIVES
EP1233780A4 (en) IDENTIFICATION OF THE SORTASEGEN
DK1095021T3 (en) quinoline
DE69904162D1 (en) quinoline
DE69904333D1 (en) quinoline
ATE317396T1 (en) 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENS
ATE352210T1 (en) PREVENTING HARD CONFECTS FROM STICKING
SI1114031T1 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
SE9900001D0 (en) The self-gluing wallpapers
SE9903503D0 (en) Universal holder
SE9900631D0 (en) Carton Alarm
IT1308149B1 (en) MODIFIED TOOL HOLDER.
SE9901903D0 (en) Novel process
SE9900694D0 (en) Novel process
FI991398A0 (en) Kitchen roll blank